Search
Triheptanoin
go.drugbank.com/drugs/DB11677ApprovedInvestigational[A214812,A214817] Complications in lc-FAOD patients are reduced from approximately 60% to approximately 10% with the addition of triheptanoin. … [L14612] In clinical trials, patients with long chain fatty acid oxidation disorders (lc-FAODs) treated with triheptanoin are less likely to develop hypoglycemia, cardiomyopathy, rhabdomyolysis, and hepatomegaly
Acebutolol
go.drugbank.com/drugs/DB01193ApprovedInvestigationalA cardioselective beta-adrenergic antagonist with little effect on the bronchial receptors. … The drug has stabilizing and quinidine-like effects on cardiac rhythm as well as weak inherent sympathomimetic action.
Synonyms: N-(3-acetyl-4-[2-hydroxy-3-(isopropylamino)propoxy]phenyl)butanamide, N-[3-acetyl-4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]phenyl]butanamideEmbusartan
go.drugbank.com/drugs/DB19949ExperimentalEmbusartan is a small molecule drug. The usage of the INN stem '-sartan' in the name indicates that Embusartan is a angiotensin II receptor antagonist, antihypertensive (non-peptidic).
Categories: Angiotensin II receptor antagonists, Angiotensin II Type 1 Receptor BlockersPotassium aspartate
go.drugbank.com/drugs/DB15819ApprovedWithdrawnMixtures: TROMCARDİN 0,5 G + 0,5 G/10 ML IV ENJEKSİYONLUK ÇÖZELTİ (5 AMPUL)Rifabutin
go.drugbank.com/drugs/DB00615ApprovedInvestigationalA broad-spectrum antibiotic that is being used as prophylaxis against disseminated Mycobacterium avium complex infection in HIV-positive patients.
Synonyms: 4-N-isobutylspiropiperidylrifamycin S, 4-Deoxo-3,4-(2-spiro(N-isobutyl-4-piperidyl)-2,5-dihydro-1H-imidazo)-rifamycin SPlazomicin
go.drugbank.com/drugs/DB12615ApprovedOn June 28th, 2018, plazomicin sulfate was approved by the FDA for use in adult patients for the treatment of complicated urinary tract infections (cUTI) including Pyelonephritis. … It is marketed as Zemdri and is administered via once-daily intravenous infusion.
Ambenonium
go.drugbank.com/drugs/DB01122ApprovedWithdrawnAmbenonium is a cholinesterase inhibitor. It is used in the management of myasthenia gravis.
Vimseltinib
go.drugbank.com/drugs/DB17520ApprovedInvestigationalin a lower risk of off-target effects, including hepatotoxicity. … [L52230,A265035] Vimseltinib - under the brand name Romvimza - was approved by the FDA in February 2025 for the treatment of tenosynovial giant cell tumours for which surgical resection is not appropriate
Argatroban
go.drugbank.com/drugs/DB00278ApprovedInvestigationalArgatroban is a non-heparin anticoagulant shown to both normalize platelet count in patients with HIT and prevent the formation of thrombi. … The American College of Cardiologists (ACC) recommend using bivalirudin or argatroban in patients who have had, or at risk for, heparin induced thrombocytopenia (HIT) and are undergoing percutaneous coronary
Hyoscyamine
go.drugbank.com/drugs/DB00424ApprovedInvestigational[L31548,L31553] Although hyoscyamine is marketed in the United States, it is not FDA approved.[L31548,L31553] … Hyoscyamine is a tropane alkaloid and the levo-isomer of [atropine].[A228423] It is commonly extracted from plants in the _Solanaceae_ or nightshade family.
Mixtures: UR N-C Urinary Antiseptic